Keyphrases
Resistance Mechanisms
100%
Triple-negative Breast Cancer
100%
Cell-based
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Metastatic Triple-negative Breast Cancer
62%
Triple-negative Breast Cancer Cells
50%
Clinical Setting
50%
T Cells
37%
Antitumor Activity
37%
Immunotherapeutic Strategy
37%
Therapy Types
37%
T Cell Immunotherapy
25%
Tumor Antigen
25%
Breast Cancer
25%
Escape Mechanism
25%
Solid Tumors
12%
Leukemia
12%
Chemotherapy
12%
Clinical Grade
12%
Host Immune Response
12%
Oncologists
12%
Phase I Clinical Trial
12%
Targeted Therapy
12%
Recurrent Disease
12%
Animal Model System
12%
Grant Proposal
12%
Metastasis
12%
Antigen-specific
12%
Genetic Engineering
12%
Novel Therapeutics
12%
Hypoxia
12%
Solid Tumor Therapy
12%
Targeted Treatment
12%
Collaborative Programs
12%
Tumor Cells
12%
Immune System
12%
Therapeutic Efficacy
12%
Young African American Women
12%
Effective Therapy
12%
Rational Design
12%
Patient Mortality
12%
Tumor Microenvironment
12%
Medicine and Dentistry
Immunotherapy
100%
Chimeric Antigen Receptor T-Cell
100%
Triple Negative Breast Cancer
100%
Cancer Cell
25%
T Cell
18%
Antineoplastic Activity
18%
Targeted Therapy
12%
Breast Cancer
12%
Solid Malignant Neoplasm
12%
Immune System
12%
Tumor Antigen
12%
Tumor Microenvironment
6%
Leukemia
6%
Metastatic Carcinoma
6%
Hypoxia
6%
Side Effect
6%
Recurrent Disease
6%
Combination Therapy
6%
Clinical Trial
6%
Oncologist
6%
Clinical Finding
6%
Tumor Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Triple Negative Breast Cancer
100%
Neoplasm
25%
Solid Malignant Neoplasm
12%
Tumor Antigen
12%
Breast Cancer
12%
Side Effect
6%
Hypoxia
6%
Clinical Trial
6%
Tumor Microenvironment
6%
Chimeric Antigen Receptor
6%
Combination Therapy
6%
Leukemia
6%
Chemotherapy
6%
Recurrent Disease
6%